Synthesis of <i>N</i>-(Hetero)aryl Carbamates via CuI/MNAO Catalyzed Cross-Coupling of (Hetero)aryl Halides with Potassium Cyanate in Alcohols
作者:S. Vijay Kumar、Dawei Ma
DOI:10.1021/acs.joc.7b03175
日期:2018.3.2
to N-(hetero)aryl carbamates was developed through CuI/MNAO [2-((2-methylnaphthalen-1-yl)amino)-2-oxoacetic acid] catalyzed cross-coupling of (hetero)aryl chlorides with potassium cyanate in alcohols at 120–130 °C. This method utilizes broadly available substrates to afford various N-(hetero)aryl carbamates in good to excellent yields. Moreover, (hetero)aryl bromides and (hetero)aryl iodides were also
Readily available phosphoramidites incorporating TADDOL-related diols with an acyclic backbone turned out to be excellent ligands for asymmetric gold catalysis, allowing a number of mechanistically different transformations to be performed with good to outstanding enantioselectivities. This includes [2 + 2] and [4 + 2] cycloadditions of ene-allenes, cycloisomerizations of enynes, hydroarylation reactions
COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY
申请人:Liu Hong
公开号:US20100234365A1
公开(公告)日:2010-09-16
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).
[EN] COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS UTILISÉS COMME INHIBITEURS DE L'ACTIVITÉ DU RÉCEPTEUR CANNABINOÏDE 1
申请人:IRM LLC
公开号:WO2008076754A2
公开(公告)日:2008-06-26
[EN] The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1). [FR] La présente invention concerne des composés, des compositions pharmaceutiques contenant ces composés et des méthodes d'utilisation de ces composés pour traiter ou prévenir des maladies ou des troubles associés à l'activité du récepteur cannabinoïde 1 (CB1).